Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a research report report published on Tuesday. They currently have $7.00 price target on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Separately, Leerink Swann reaffirmed an outperform rating on shares of Kura Oncology in a report on Monday, November 7th. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average price target of $14.80.
Kura Oncology (NASDAQ:KURA) remained flat at $6.30 on Tuesday. 15,704 shares of the company’s stock traded hands. The stock’s 50 day moving average is $5.64 and its 200 day moving average is $5.09. The stock’s market capitalization is $119.98 million. Kura Oncology has a 12 month low of $2.50 and a 12 month high of $7.89.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.03. On average, analysts predict that Kura Oncology will post ($1.49) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Upgraded to “Buy” by Zacks Investment Research” was posted by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be read at https://baseballnewssource.com/markets/kura-oncology-inc-kura-upgraded-to-buy-by-zacks-investment-research/345629.html.
Hedge funds have recently added to or reduced their stakes in the company. Minerva Advisors LLC acquired a new stake in Kura Oncology during the second quarter worth $977,000. Alethea Capital Management LLC acquired a new stake in Kura Oncology during the second quarter worth $168,000. Pillar Pacific Capital Management LLC acquired a new stake in Kura Oncology during the third quarter worth $191,000. Finally, Partner Investment Management L.P. raised its stake in Kura Oncology by 2.7% in the third quarter. Partner Investment Management L.P. now owns 23,646 shares of the company’s stock worth $148,000 after buying an additional 623 shares during the last quarter. Hedge funds and other institutional investors own 45.64% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with our FREE daily email newsletter.